Share Name Share Symbol Market Type Share ISIN Share Description
Angle Plc LSE:AGL London Ordinary Share GB0034330679 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.50p +1.08% 47.00p 46.00p 48.00p 47.00p 46.50p 46.50p 99,106.00 16:23:50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Support Services 0.4 -5.4 -8.6 - 35.16

Angle Share Discussion Threads

Showing 44726 to 44747 of 44750 messages
Chat Pages: 1790  1789  1788  1787  1786  1785  1784  1783  1782  1781  1780  1779  Older
DateSubjectAuthorDiscuss
28/3/2017
15:37
I doubt the share price fall means any more than the share price rise did a few weeks ago personally, except possibly as an indication that trial "headline figure" news may not be forthcoming till June or even later. Http://www.wvalways.com/story/34799965/circulating-tumor-cells-ctc-technologies-market-2017-global-trend-segmentation-and-opportunities-forecast-to-2022 The latest CTC Industry movers and shakers report on offer at the usual rip off prices, AGL make the cut but not Vortex (They like to restrict it to 50 companies FWIW) I love this quote from the teaser. "Several companies throughout the world have products in clinical trials and are expected to compete vigorously in the next few years with improvised products."
banshee
28/3/2017
15:29
The company has a great product but we all know that 99,999 times out of 100,000 the market knows what is going on before we do - whispers, etc. So, if all is going so well why is the share price drifting badly? I view the market as an information exchange, we buy and sell on information and so do others. So, if things are so good why is there constant selling of the shares? The numbers are not massive but the share price fall has so far failed to attract buyers. If I didnt know better I would say there was a discounted fund raising on the way but we dont need cash so this cannot be true. For the record I hold a very large position in these shares and still believe in the product but dont give me that rubbish about investors not managing their own expectations. AN and others have published astonishingly positive comments and AN has also emailed and spoken with investors about big things ahead. Even the latest European trial, which is great news, is not concluded until after 2020. To me it seems as though the market is getting bored with jam tomorrow and needs to see things happening now. Again, for the avoidance of doubt, love the product but have diminishing confidence in the management. That lady the company took on in the US is a big player and on big wages, has she been twiddling her thumbs for 2 years? What was the point of the ADR listing if the company was looking longer term. Simple fact is the company's timescales have all slipped and they need to regain control again.
alloa2003
28/3/2017
13:38
"alloa200328 Mar '17 - 08:52 - 5564 of 5572 1 0 Its all about managing expectations - they have failed badly in this area." I think the problem actually lies with some investors failing to manage their own expectations. That isn't the company's fault.
impvesta
28/3/2017
12:49
Jelenko, that is my view aswell. And if the price was £1 and everything else within the company was the same people wouldn't be complaining, and they probably wouldn't be selling either.
stevelauren23
28/3/2017
12:48
Have to agree with you Alloa re expectations One of ANs current expectations is that the breast trial in USA will be concluded and FDA application in by the end of this year.. This is what he has said and we now have just 9 months left
life guard
28/3/2017
12:47
How do you know he wasn't given those timescales from other people involved, like the FDA. He has been delivering for years now, but unfortunately in the beginning delivering isn't making loads of money, it is making consistent progress. If you look at what they are on verge of, even just with the ovarian trial, how anyone can say he isn't doing his job well is beyond me. Add into that all the validations we now receive on a regular basis, so many now that we don't even hear about when Parsortix is being presented at various shows by cancer specialists. The next big step is clinical trial results, which we are now due within a couple of months. We are much further ahead that this time last year!
stevelauren23
28/3/2017
12:46
From memory he has said that the timing was down to the fda and also that the completion time for the various trials was down to the KOL's etc.I'm sure that all shareholders frustrated at the share price The silver cloud is that more shares can go into the new ISA period. We are not far from the Ovarian reults really, so far things look good in that respect. The company say that the target market fior Ovarian is worth £300m to them. If that is the case I think the current share price is justified at only 1% of that market. That's my own view.
jelenko
28/3/2017
12:24
"Take the high salary out of the equation and he's as solid as you can get." - he gets the high salary so why do you say this? When you take a big salary and shares you have to start delivering. I dont disagree they have a great product but expectations have not been managed well. We know FDA clearance takes time so why has AN given his own expected timescale in the past. He should have said nothing and said it was out of his hands.
alloa2003
28/3/2017
09:48
Zeus, I think you are forgetting that everyone here is an expert, they have all taken similar products from start to finish and sold the final product to a big pharmaceutical company for billions of pounds, so they know what they are talking about and could all do a better job than Andrew. Oh no, sorry I forgot that's not the case, in fact actually no one here has done that, and very few (if any) will even work or have any experience in this field. So while they all think they can do better, really they'd not know where to start. People only think AN is doing a bad job because he's not made them rich yet. I judge AN on where we are now from 1 year ago, and progress from previous years. And personally I think he's making good progress in every area. FDA approval has taken longer to come than we expected, but that doesn't mean there isn't progress. Obviously time will tell over wether we will eventually be a commercial success, but from what I've seen over the last few years AN is as good a man as any to get us there.
stevelauren23
28/3/2017
09:24
So what would you gents have done differently? Obviously with the advantage of hindsight? And taking on board that FDA approval is out of our hands... Newland is a good CEO. Take the high salary out of the equation and he's as solid as you can get. The reason why we have so many institutional investors on board!
zeus19
28/3/2017
09:14
A vote of no confidence in Newland might shake things up a bit.
nigelc43
28/3/2017
08:52
Its all about managing expectations - they have failed badly in this area.
alloa2003
28/3/2017
08:30
The results due are all important. If it was that easy there would already be another FDA approved device in use. We are still on track to be the first.
mikepompeyfan
28/3/2017
08:06
Fair valid points made. I hope ....when we finally get the results there will be confirmation of the immediate income that will be derived from sales...
life guard
28/3/2017
07:53
You are right about about patience Willfy, but I think we are all a bit disappointed about slow progress. However, I these matters are in the hands of others and are always slow: it is easy to moan about the management, but I'm sure they would like to get this to market with a route to retirement sooner rather than later. Their possible capital gain from success dwarfs the current (possibly high) salaries.
semper vigilans
27/3/2017
22:25
I believe in the product but my belief in the management is being tested to the limit at the moment. No more bullsh*t, no more jam tomorrow lets deal on cold hard facts and tells us where the income is coming from, where the funds from last years fund raising went to and why are they keeping the name of this "mystery partner" secret. Ploughing millions of pounds into trials and losing focus on actually bringing money in is commercial suicide.
alloa2003
27/3/2017
22:05
It is fair to say this has been a very frustrating share to hold. I am glad I reduced when I did but I still have a few thousand shares left. I really hope we have significant news in the next few weeks.
rafboy
27/3/2017
21:40
Believe me, No one is more disappointed in the current share price than me, I also have a large holding, and it's going to stay a large holding, whilst this as been an extremely frustrating share to hold, I genuinely believe the end game is in sight..Actually Alloa , it's 3 long yrs since Angle applied for the FDA clearance, but now with both results due in Q2 from the Ovarian trials, Patience again is the key word......
willfy
27/3/2017
21:20
Spot on! escapetohome - 19 Dec 2016 - 19:58:52 - 4656 of 5557 ANGLE 2016 – LIQUID BIOPSY TAKEOVER TARGET - AGL Judging by the sawtooth upward and downward oscillations in 2013 , the next support is 50p then 45 p if that doesnt hold.
escapetohome
27/3/2017
21:17
Excellent post Alloa, its only though what a few have been saying for a couple of years. I completely sold out, except for my pension holding. For my pensions sake i hope these recover.
escapetohome
27/3/2017
21:08
Enough is enough. I have a very large holding in these shares and while I go in with my eyes wide open and do my research I expect the management to be upfront with shareholders. Quietly all of the targets this management has ever set have slipped by and 2 years after approaching the FDA there is still no news. The management can no longer hide behind "there are things going on we can't discuss" and "there is news soon" rubbish, the announcements say all is going well but the share price says differently. Don't believe this drivel about people selling out before the end of the tax year and they will buy back later. If that was the case then sellers would buy via another vehicle to ensure they are not out of the shares in case something was to happen. Also, if there was good news to follow or things going on in the background then there would still be buyers out there - "informed buyers" - so I don't buy into this end of tax year stuff. If the shares offer such good value lets see the directors actually putting their hands into their pockets rather than sitting there banking shares and bonuses while paid up shareholders suffer. I believe the company has a life saving product but over the last couple of years the only winners have been the directors and the so called experts we have taken on board. Its about time the directors and their representatives in the US started to deliver - we were promised big things were happening in America but so far absolutely nothing of substance. I have held my peace for 2 years now watching the company "progress" but we are at a crossroads now, either the existing management start to be up front and deliver or they step aside and let someone else do it. There is a grave danger that a life saving product could be ruined as everything is jam tomorrow while competitors are catching up.
alloa2003
27/3/2017
17:55
What a dog of a share this has turn out to be .seven year in and still waiting for jam tomorrow. Could have made more on the horses . No donkeys!!!!!!!!!!
wailo
Chat Pages: 1790  1789  1788  1787  1786  1785  1784  1783  1782  1781  1780  1779  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:30 V: D:20170329 05:27:52